Twitter Beğeni Hilesi

Heinz Wiendl (Ge) presenting biomarkers post-cladribine treatment (MAGNIFY study). Immune reconstitution towards more homeostatic and less pathogenic status. Also effects on OCBs in csf were seen! More effects on B-cells This shows real immune changes 💪🏻 #ECTRIMS2024

Yesterday new changes to the McDonald diagnostic criteria for MS were revealed ECTRIMS. The central vein sign can now be used to support the diagnosis of MS. But how should lesions be assessed for the CVS? Come and find out more at P688! #ECTRIMS2024 Neurology Research NUH

Poster presentation at #ECTRIMS2024 in #Copenhagen what a fantastic event and loads of great work!!

Grateful to have been part of the update and launch of the Oxford Health Policy Forum campaign MS Brain Health’s new report “Brain Health: Time Matters” which now includes #NMOSD & #MOGAD at #ECTRIMS 🧠 Mitzi Joi Williams, MD, FAAN European MS Platform MS Int'l Federation Gavin Giovannoni, aka Prof G

Fascinating talk by Sudarshini Ramanathan on B cells tolerance in #NMOSD #ECTRIMS2024. Sydney Health Brain & Mind Centre Kids Research

Happening TOMORROW: ECTRIMS Patient Community Day is almost here! Tune in for two interactive sessions exploring MS research and treatment, promising new therapies, and lifestyle changes that could impact you. Don’t miss it! Register now: : ectrims.eu/ectrims2024-pa…

MS nursing: This slide is very important for nurses taking care of MS patients. UConn Health American Academy of Neurology National MS Society UConn Neurology Residency

Watch the on-demand broadcast to listen to experts discuss how NOURIANZ® (istradefylline) works differently for “off” episodes for patients with PD. bit.ly/47OVUS4 See Prescribing Information for NOURIANZ bit.ly/3KSzp5l

It’s the final day of #ECTRIMS2024! Late-breaking data are set to be presented, and patient focused sessions will close out the meeting. Although the Congress wraps up today our coverage does not! Head to NeurologyLive.com/ECTRIMS to get all the news from the meeting.

Thanks to all the late-breaking presenters—and to the audience for asking so many excellent questions. There is a lot to digest from this session here at #ECTRIMS2024. Keep an eye out for our coverage of the presentations on NeurologyLive®!

A new analysis from the MAGNIFY-MS study suggested that treatment with cladribine tablets resulted in low overall disability accrual in patients with highly-active #MultipleSclerosis. EMD Serono #ECTIRMS2024 ECTRIMS Università Vita-Salute San Raffaele neurologylive.com/view/cladribin…

From #ECTRIMS2024 late-breaking session: The positive finding on the secondary end point of 6-month confirmed disability worsening in GEMINI 1 and 2 supports the data from the phase 3 HERCULES trial in secondary progressive multiple sclerosis. Read more: neurologylive.com/view/tolebruti…

Data from a phase 3 study suggested a 450-mg dose of ublituximab-xiiy can be administered in 1 hour as the initial infusion for patients with #MS who are B-cell depleted without additional safety concerns. TG Therapeutics ECTRIMS #ECTRIMS2024 Rocky Mountain MS neurologylive.com/view/enhance-d…

A study revealed nearly 1/5 of all lesions remyelinated over a 2-year period with cladribine, an FDA-approved disease-modifying therapy, among patients with highly active relapsing-remitting #MultipleSclerosis. EMD Serono ECTRIMS #ECTRIMS2024 PUCRS International neurologylive.com/view/remyelina…

🗣️🎙️We recently spoke with Peter Calabresi, of Johns Hopkins University, who discussed the new updates to the #MultipleSclerosis diagnostic criteria presented at #ECTRIMS2024, held September 18-20, in Copenhagen, Denmark. 🎥 🧠 Check out the interview on our site now! ECTRIMS

Take 5️⃣ minutes to stay up-to-date with our #FridayFive today! 👉 National MS Society Blog Post 👉 Guest Article w/ CareYaya 👉 #ECTRIMS2024 w/ Peter Calabresi 👉 NeuroVoices w/ Dr Antonio Scalfari 👉 Mind Moments w/ Edgewise Therapeutics 🖐 neurologylive.com/view/neurology…

We also spoke with Valentin Krüger, MD, of University Hospital Frankfurt, who talked about a study presented at #ECTRIMS2024 that analyzed time delays in initiating high-efficacy treatments in patients with #MultipleSclerosis. Here's a clip of the conversation! ECTRIMS 🇩🇪 📹👇

📙 During #ECTRIMS2024, we share a new blog that features Nicole M. Boschi, PhD, of the National MS Society, who talked about the impact of the upcoming Medicare Part D and Medicare Advantage changes for the #MS community. Check it out on our site now! 🧡

Recently, we talked with Shamik Bhattacharyya, of Harvard Medical School and Brigham and Women's Hospital, who discussed a study presented at #ECTRIMS2024 that compared the effectiveness and safety profiles of FDA-approved #NMOSD therapies with other commonly used treatments. ECTRIMS